Swaminathan Padmanabhan (Padmanabhan) Iyer MD

PubMed

• 1 citations
  Association of PET4 response with outcomes of BV-CHP vs CHOP in the ECHELON-2 trial in CD30+ peripheral T-cell lymphoma.
  Swaminathan Iyer, Neha Mehta-Shah, Ranjana Advani, Nancy L Bartlett, Jacob H Christensen
  Blood Advances. 2025-12-09
• Clinical Trial Success Rate in Lymphoma: Fate of Trials and Agents from 2000 to 2019.
  Zhiping Luo, Meng Li, Brian Primeaux, Rahul Shah, Ruitao Lin
  Blood Advances. 2025-11-07
• Racial differences in mycosis fungoides and Sézary syndrome: A multicenter cohort study.
  Pamela B Allen, Subir Goyal, Swaminathan Iyer, Sai Talluru, Auris Huen
  Journal of the American Academy of Dermatology. 2025-09-29

Journal Articles

• A unique aptamer-drug conjugate for targeted therapy of multiple myeloma  
  Wen J, Tao W, Hao S, Iyer SP, Zu Y., Leukemia, 8/5/2015
• A Phase IB multicentre dose-determination study of BHQ880 in combination with anti-myeloma therapy and zoledronic acid in patients with relapsed or refractory multiple...  
  Iyer SP, Beck JT, Stewart AK, Shah J, Kelly KR, Isaacs R, Bilic S, Sen S, Munshi NC, Br J of Haematol, 8/1/2014
• BET protein antagonist JQ1 is synergistically lethal with FLT3 tyrosine kinase inhibitor (TKI) and overcomes resistance to FLT3-TKI in AML cells expressing FLT-ITD  
  Fiskus W, Sharma S, Qi J, Shah B, Devaraj SG, Leveque C, Portier BP, Iyer SP, Bradner JE, Bhalla KN, Mol Cancer Ther, 7/1/2014

Books/Book Chapters

• Breast Cancer- A Practical Guide 
  Iyer SP et al.Editors: Silva, Orlando E. & Zurrida, Stefano.Elsevier Saunders PublishersEdition 3rd,2005

Abstracts/Posters

• Radiation Therapy Can be an Effective Bridging Strategy Prior to Axicabtagene Ciloleucel Therapy for Relapsed/Refractory Large B-Cell LymphomaRadiation Therapy Can be ...
  Swaminathan P. Iyer, 61st Annual American Society of Hematology Meeting, 61st Annual American Society of Hematology Meeting - Orlando, FL, 12/7/2019
• Novel CD4+CD8+ Umbilical Cord Blood Regulatory T Cells
  Swaminathan P. Iyer, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Analysis of Factors Predictive of Risk of Transformation and Time to Transformation in Patients (pts) with Mantle Cell Lymphoma _ Cohort Study of 369 Patients
  Swaminathan P. Iyer, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019

Lectures

• Final Results of Phase 1/1b Study of Tenalisib, Dual PI3K _/_ Inhibitor in Patients with Relapsed/Refractory T-Cell Lymphoma 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• A Phase I/II Study to Examine the Safety and Efficacy of Pembrolizumab 200 Mg Fixed Dose Administered Every 3 Weeks (Q3W) in Combination with Romidepsin in Relapsed or... 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• Safety of Axicabtagene Ciloleucel CD19 CAR T-Cell Therapy in Elderly Patients with Relapsed or Refractory Large B-Cell Lymphoma 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018